This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Cellivery Therapeutics Past Earnings Performance

Past criteria checks 0/6

Cellivery Therapeutics's earnings have been declining at an average annual rate of -6.3%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 36.7% per year.

Key information

-6.3%

Earnings growth rate

-9.1%

EPS growth rate

Life Sciences Industry Growth	53.7%
Revenue growth rate	36.7%
Return on equity	n/a
Net Margin	-69.4%
Last Earnings Update	30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Cellivery Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A268600 Revenue, expenses and earnings (KRW Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 24	8,831	-6,127	2,812	1,961
30 Jun 24	11,193	-9,429	4,700	1,216
31 Mar 24	14,494	-20,314	289	6,946
31 Dec 23	18,863	-32,571	9,644	6,946
30 Sep 23	39,130	-83,317	41,529	18,755
30 Jun 23	34,994	-85,507	43,512	22,322
31 Mar 23	30,457	-82,316	51,501	17,477
31 Dec 22	23,158	-75,159	44,381	19,115
30 Sep 22	4,306	-30,831	18,521	7,437
30 Jun 22	4,223	-32,762	18,366	8,097
31 Mar 22	4,008	-31,276	19,926	8,449
31 Dec 21	3,872	-28,069	18,676	7,708
30 Sep 21	367	-25,031	15,810	6,727
30 Jun 21	455	-21,033	14,191	4,387
31 Dec 20	762	-17,248	10,094	5,697
31 Dec 18	4,512	-6,698	4,552	410
31 Dec 17	2,774	-15,008	3,548	223

Quality Earnings: A268600 is currently unprofitable.

Growing Profit Margin: A268600 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A268600 is unprofitable, and losses have increased over the past 5 years at a rate of 6.3% per year.

Accelerating Growth: Unable to compare A268600's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A268600 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (39.6%).

Return on Equity

High ROE: A268600's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/06 14:49
End of Day Share Price	2025/03/06 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cellivery Therapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.